We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Two-Part Study of BOTOX® Therapy for Ischemic Digits

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01309802
First Posted: March 7, 2011
Last Update Posted: June 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Southern Illinois University
Results First Submitted: July 28, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Raynaud's Disease
Intervention: Drug: onabotulinum toxin type-A

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo no intervention
Onabotulinum Toxin Type-A

up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1

onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1


Participant Flow:   Overall Study
    Placebo   Onabotulinum Toxin Type-A
STARTED   25   23 
COMPLETED   13   14 
NOT COMPLETED   12   9 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo no intervention
Onabotulinum Toxin Type-A

up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1

onabotulinum toxin type-A: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1

Total Total of all reporting groups

Baseline Measures
   Placebo   Onabotulinum Toxin Type-A   Total 
Overall Participants Analyzed 
[Units: Participants]
 25   23   48 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      23  92.0%      19  82.6%      42  87.5% 
>=65 years      2   8.0%      4  17.4%      6  12.5% 
Age 
[Units: Years]
Mean (Full Range)
 53.3 
 (24 to 73) 
 49.2 
 (26 to 70) 
 51.3 
 (24 to 73) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      21  84.0%      19  82.6%      40  83.3% 
Male      4  16.0%      4  17.4%      8  16.7% 
Region of Enrollment 
[Units: Participants]
     
United States   25   23   48 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Patient Reported Pain-free Days   [ Time Frame: baseline to 28 days ]

2.  Secondary:   Quality of Life   [ Time Frame: change from baseline to 28 days ]

3.  Secondary:   Hand Function   [ Time Frame: baseline to 28 days ]

4.  Secondary:   Patient Satisfaction   [ Time Frame: baseline to 28 days ]

5.  Secondary:   Tissue Perfusion   [ Time Frame: baseline to 28 days ]

6.  Secondary:   EQ-5D A Standardised Patient Reported Measure of Health Status for Clinical and Economic Appraisal   [ Time Frame: baseline to 28 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Research Administrator
Organization: Southern Illinois University School of Medicine
phone: 217-545-2531
e-mail: surgeryresearch@siumed.edu


Publications:

Responsible Party: Southern Illinois University
ClinicalTrials.gov Identifier: NCT01309802     History of Changes
Other Study ID Numbers: NEU-SIUSOM-11-001
First Submitted: March 4, 2011
First Posted: March 7, 2011
Results First Submitted: July 28, 2016
Results First Posted: June 2, 2017
Last Update Posted: June 2, 2017